EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder

Xiaofeng Wang, Luann Phillips, Matthew Harlin, Karimah S Bell Lynum, Frank Larsen, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Ric M Procyshyn, Craig Chepke, Julie Passarell

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Xiaofeng Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacometrics, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA. Hauptthemen laut MEDLINE: Aripiprazole, Bipolar Disorder, Antipsychotic Agents, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aripiprazole once‐monthly (AOM) is approved for the maintenance monotherapy treatment of bipolar I disorder (BP‐I) in adults. A previously developed population pharmacokinetic model was validated by applying it to data from patients diagnosed with BP‐I. The model was then used to generate aripiprazole exposures for an exposure‐response model intended to describe the relationship between aripiprazole exposure and time to recurrence of any mood episode in patients with BP‐I. The BP‐I data were best described by a continuous model in which higher aripiprazole exposure was associated with a lower risk of recurrence. For each 1 ng/mL increase in aripiprazole plasma concentration, the predicted hazard for recurrence decreased by 0.34%. An aripiprazole plasma concentration of 95 ng/mL (clinically relevant in schizophrenia) was tested in a separate categorical model and was a significant predictor of time to recurrence ( P = .0270), with a 36% (1.55‐fold) decrease in the predicted risk of recurrence with an aripiprazole concentration of ≥95 versus

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazoleBipolar DisorderAntipsychotic AgentsModels, BiologicalHumansAdultMaleFemaleMiddle AgedRecurrenceDrug Administration ScheduleYoung AdultDose-Response Relationship, Drug

Stichwörter der Autor:innen

antipsychotic treatmentlong‐acting injectablepharmacokinetic modelingpopulation pharmacokinetics

Substanzen

AripiprazoleAntipsychotic Agents

Autor:innen und Institutionen

  • Pharmacometrics, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
  • Simulations Plus, Inc., Clinical Pharmacology and Pharmacometrics Business Unit, Buffalo, NY, USA.
  • Discovery Research, Early Phase and Translational Medicine, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
  • Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
  • Clinical & Quantitative Pharmacology, H. Lundbeck A/S, Valby, Denmark.
  • Global Medical Affairs, H. Lundbeck A/S, Valby, Denmark.

Zitieren

APA

Wang, X., Phillips, L., Harlin, M., Bell Lynum, K. S., Larsen, F., Such, P., Madera-McDonough, J., Yildirim, M., Procyshyn, R. M., Chepke, C., & Passarell, J. (2025). Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1580

Vancouver

Wang X, Phillips L, Harlin M, Bell Lynum KS, Larsen F, Such P, et al. Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1580

BibTeX
@article{Wang2025,
  author = {Wang, Xiaofeng and Phillips, Luann and Harlin, Matthew and Bell Lynum, Karimah S and Larsen, Frank and Such, Pedro and Madera-McDonough, Jessica and Yildirim, Murat and Procyshyn, Ric M and Chepke, Craig and Passarell, Julie},
  title = {Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1580}
}
Kostenlos starten →